

ALPIC 2015

Advanced Learning on Plateles & Thrombosis International Course

March, 20-22, 2015

Miramonte Hotel

PALIOS AGIOS ATHANASIOS

GREECE

Organized by



Institute for the Study and Education
on Thrombosis and Antithrombotic Therapy



Atherothrombosis Research Centre,
University of Ioannina

Course Directors

Alexandros Tselepis

Professor of Biochemistry-Clinical Chemistry
Department of Chemistry, University of Ioannina

John Goudevenos

Professor of Cardiology, Faculty of Medicine,
School of Health Sciences, University of Ioannina

Under the auspices of:



European and Mediterranean League
Against Thrombotic Diseases



Hellenic Cardiological Society

Endorsed by:



International Society
on Thrombosis and Haemostasis

The course
has been accredited
with 11 CME credits
by the
Panhellenic Medical
Association

www.alpic2015.gr

FINAL PROGRAMME

Eliquis[®] apixaban

ELI-25-MARY4.432GR13PR08685-02



Bristol-Myers Squibb



Λιανικές Τιμές: BT 20 F.C.T x 2,5mg: 29,50€. BT 60 F.C.T x 2,5mg: 88,35€. BT 60 F.C.T x 5mg: 85,78€.

*Για πλήρεις συνταγογραφικές πληροφορίες συμβουλευθείτε
την Π.Χ.Π. του προϊόντος που διατίθεται από την εταιρία.*



Bristol-Myers Squibb

Bristol-Myers Squibb A.E.

Αττικής 49-53 & Προποντιδός 2, Τ.Κ.: 152 35 Βριλήσσια, Αττική
ΤΘ 63833-Βριλήσσια Τ.Κ. 152 03, Αττική
Τηλ.: 210 6074300 & 210 6074400, Φαξ: 210 6074333
ΑΡ.Μ.Α.Ε. 62772/01ΑΤ/Β/07/148



PFIZER HELLAS A.E.

Λεωφ. Μεσογείων 243, 154 51 Ν. Ψυχικό,
Τηλ. Επιστημονικής Ενημέρωσης: 210 67 85 800

ΓΙΑ ΚΑΛΥΤΕΡΑ ΑΠΟΤΕΛΕΣΜΑΤΑ
ΞΕΚΙΝΑΜΕ ΑΠΟ ΕΔΩ



BRILIQUE™
ticagrelor

Νέα Εποχή στα Αντιαιμοπεταλιακά.

ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ. Κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 90 mg ticagrelόρη.
Πριν από τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών Προϊόντος.
Η Περίληψη των Χαρακτηριστικών του Προϊόντος περιέχεται εντός του εντύπου.

Για περισσότερες πληροφορίες, απευθυνθείτε στην

AstraZeneca 

Θεοτοκοπούλου 4 & Αστροναυτών, 151 25 Μαρούσι, Αθήνα
Τηλ.: 210 6871500, Fax: 210 6859195 • Τηλ. παραγγελιών: 210 5596970-72, Fax: 210 5596973
www.astrazeneca.gr

Welcome Message 5

ALPIC Organizers & Committees 6

General Information 7-10

Scientific Program

 Friday, March 20th, 2015 11-12

 Saturday, March 21st, 2015 13-17

 Sunday, March 22nd, 2015 18-23

Index/ Invited Faculty 24-28

Sponsors 29

Dear Colleagues

We are pleased to welcome you to **ALPIC 2015** (Advanced Learning on Platelets & Thrombosis International Course), the fifth international scientific event on Platelets and Thrombosis, taking place this year in PaliosAgios Athanasios village, at Miramonte Hotel, Pella, Greece, on **March 20-22 2015**.

ALPIC 2015 is organized by the **Institute for the Study and Education on Thrombosis and Antithrombotic Therapy** as well as the **Atherothrombosis Research Centre of the University of Ioannina**, under the auspices of the **European and Mediterranean League Against Thrombotic Diseases (EMLTD)** and the **Hellenic Cardiological Society**. The Course is also endorsed by the **International Society on Thrombosis and Haemostasis (ISTH)**.

The Course aims to serve as a knowledge transfer forum for scientists in the current aspects of Platelet and Thrombosis research, ranging from the basic science to the clinical practice. The scientific program is designed to highlight the rapid development and ongoing evolution on the pathophysiology of Thrombosis along with discussion regarding all current advances in Antiplatelet and Anticoagulant therapy.

An internationally recognized panel of invited speakers will present state-of-the art lectures on the above scientific fields and will create an excellent opportunity for all participants to stimulate an extended and very constructive discussion both inside and outside the lecture hall.

The magnificent location and the picturesque landscapes offered by Palios Agios Athanasios, a traditional village, situated on Kaimaktsalan Mountain, with stone built houses with tiles, built according to the local Macedonian architecture, will add to the scientific quality of the presentations, making this event a remarkable one for all participants. The Organizers will spare no efforts to ensure that ALPIC 2015 will be an exciting and enriching experience.

At this point we would like to extend our sincere thanks to all those who worked with dedication, putting together this attractive and comprehensive scientific program, namely the International Invited Faculty for its warm acceptance to participate in ALPIC 2015, the Local Scientific Committee, the International Scientific Advisory Board and our sponsors for their generous support. Last but not least, we extend our warm welcome and gratitude to all colleagues for joining us at this course and sharing our enthusiasm.

We welcome you and we wish you all enjoy ALPIC 2015 in the picturesque landscape offered by PaliosAgios Athanasios village and Kaimaktsalan Mountain.

With our best regards,

John Goudevenos

Professor of Cardiology,
School of Medicine, University of Ioannina

Alexandros Tselepis

Professor of Biochemistry-Clinical Chemistry
Department of Chemistry,
University of Ioannina

Organized by:

Institute for the Study and Education on Thrombosis and Antithrombotic Therapy



Atherothrombosis Research Centre, University of Ioannina

Under the auspices of:

European and Mediterranean League Against Thrombotic Diseases



Hellenic Cardiological Society

Endorsed by:

International Society on Thrombosis and Haemostasis

Course Directors:

Alexandros Tselepis

John Goudevenos

Local Scientific Committee

Alexopoulos Dimitrios	Chalikias George	Sourmelis Savvas-George
Andrikopoulos George	Korantzopoulos Panagiotis	Stakos Dimitrios
Arnautoglou Eleni	Korompilias Anastasios	Tselepis Alexandros
Beis Ioannis	Lazaris Andreas	Tsounos Ioannis
Bobotis George	Lefkou Elmina	Tsoukatos Dimokritos
Davlouros Periklis	Matsagkas Miltiadis	Tsolakis Ioannis
Dimitriadis Dimokritos	Nikas Dimitrios	Tzimas Petros
Fousas Stefanos	Pappas Konstantinos	Vasilikos Vassilios
Giannoukas Athanasios	Parthenakis Fragiskos	Vavouranakis Emmanuel
Goudevenos John	Papaioannou Spyros	Vemmos Konstantinos
Graidis Christos	Papadopoulos Thomas	Voudris Vassilios
Hahalas George	Pipilis Athanasios	Ziakas Antonios
Kanakakis John	Richter Dimitrios	Zacharoulis Achilles

International Scientific Advisory Board

Angiolillo Dominick (USA)	Mallett Susan (UK)
Badimon Lina (Spain)	Michelson Alan (USA)
Bonello Laurent (France)	Morrow David (USA)
Cattaneo Marco (Italy)	Paganelli Franck (France)
Douketis James (Canada)	Papageorgiou Chrysoula (France)
Elalamy Ismail (France)	Patrono Carlo (Italy)
Ferreiro Jose Luis (Spain)	Price Matthew (USA)
Gerotziafas Grigoris (France)	Schaefer Katrin (Germany)
Gurbel Paul (USA)	Spyropoulos Alex (USA)
Hall Alistair (UK)	Stafylas Panagiotis (Belgium)
Heptinstall Stan (UK)	Stellos Konstantinos (Germany)

■ DATE & VENUE

ALPIC 2015 Course, is held from **Friday, March 20th** to **Sunday, March 22th 2015** in **Palios Agios Athanasios**, at **Miramonte Hotel, Pella, Greece**.

The Course commences with Registration on Friday, March 20th in the evening, and concludes on Sunday, March 22th 2015 at noon.

■ COURSE VENUE

Miramonte Hotel

Palios Agios Athanasios, Pella, Greece, Tel: +30 23810 39904

Email: info@miramonte.gr, Website: <http://www.miramonte.gr/gr/>

■ VILLAGE OF PALIOS AGIOS ATHANASIOS

Palios Agios Athanasios or Kaimaktsalan is a traditional mountainous village with stone built houses with tiles, built according to the local Macedonian architecture. The ski center transformed the village in to a winter destination and is considered to be one of the most beautiful mountain villages in Greece, with impressive restored houses turned into hotels, traditional shops and restaurants. The village of Palios Agios Athanasios is located in Pella region, 33 km from Edessa, just 123 km from Thessaloniki and 603 km from Athens.

■ ACCOMMODATION

An adequate number of rooms has been reserved in Miramonte Hotel and some complimentary reservations have been reserved in other hotels in Palios Agios Athanasios.

TIP: Do not leave your hotel arrangements too late. Requests will be honored on a first-come first-served space available basis.

For reservations, kindly contact the Administrative - Organizing Bureau, Conferre Ltd (info@conferre.gr)

■ REGISTRATIONS

Registration for the course is **free of charge**.

■ SECRETARIAT OPERATING HOURS

Friday, March 20 th 2015:	16.30 - 21.00
Saturday, March 21 st 2015:	08.30 - 14.30 & 16.00 - 21:00
Sunday, March 22 nd 2015:	09.00 - 12:30

■ LANGUAGES

The official languages of the course are **Greek** and **English**.

The English language may be used widely especially in the presentations of the speakers to encourage the interaction in all scientific sessions of the English-speaking faculty.

There will be no interpretation from English to Greek language and viceversa.

■ CREDITS

The course will be accredited with **11 CME credits** by the Hellenic Medical Society.

■ PARTICIPANTS' BADGE

All participants, upon confirmation of their registration at the Secretariat, will be provided with a name badge that bears a unique barcode. It must be clearly understood that barcode badges must be scanned before entering AND after exiting the Lecture Hall.

According to the National Organization of Medicines Regulation participation for atleast of 60% of the total duration of the scientific program must be secured and recorded!

Notes:

- It is obligatory for all participants to wear their badges always during the Course.
- Barcode name badge already used for recording attendance cannot be replaced with a second badge (as duration of attendance will not be allocated properly).
- Name badges are also necessary for admittance to the Dinners and the Lunch and to be returned to the Secretariat for receiving the Certificate(s) of Attendance.
- Time slots for breaks will not be recorded.

■ CERTIFICATES OF ATTENDANCE

All registered participants are entitled to receive a Certificate of Attendance.

The Certificate will be issued only upon display of participant badge, which will be issued by the course secretariat.

■ WEBSITE

The official course website <http://www.alpic2015.gr> will provide the participants with a wide range of information. Participants are kindly requested to visit the site regularly for all updates.

■ PPT PRESENTATIONS

All who have presentations are kindly requested to deliver their presentation(s) in PPT format to the technical support personnel at least **one (1) hour before the beginning** of the Session (in order to ensure on time they run smoothly and to be able of making any possible changes). *If the presentation is scheduled early in the morning, you are kindly requested to check your presentation with the technical support personnel the day before.*

■ EVALUATION FORM (mandatory)

All participants by the end of the Congress are requested to complete and deliver to the Secretariat a relative Evaluation Form (anonymous) as feedback of their experience during the Course.

■ SOCIAL EVENTS

Along with the conference material, during the registration on 20th of March 2015, participants will find enclosed the coupons for their meals (on Friday 20/3/2015 & on Saturday 21/3/2015) included in their accommodation package.

Participants are kindly requested to present their badge for admittance to the above meals along with the coupon valid for 1 person.

Due to the large number of participants, you are kindly requested by the Organizing Committee to respect the instructions about the distribution of participants to the different restaurants, where the meals will take place.

■ EXHIBITION

The course will be accompanied by a major exhibition where pharmaceutical and / or equipment / device industries will display relevant products and therapeutic developments. Pharmaceutical companies and medical publishers are invited to participate to the course and exhibition.

■ LIABILITY AND INSURANCE

The course Organizers cannot accept liability for personal accidents or loss ordamage to private property of participants and accompanying persons. Participants should make their own arrangements with respect to health and travel insurance.

■ ORGANIZING - ADMINISTRATIVE BUREAU/ SECRETARIAT

Conferre Ltd: *"The Art of Bringing People Together"*
St. Niarhou Avenue, GR 451 10 Ioannina, Greece
Tel: +30 26510 68610, Fax: +30 26510 68611
E-mail: info@conferre.gr, Website: www.conferre.gr

Friday, March 20th, 2015**16.30-18.15 Registrations**

18.15-18.30 Welcome addresses

Vice-Rector of the University of Ioannina

Thomas Bakas (Greece)

President of the European and Mediterranean League
against Thrombotic Diseases (EMLTD)

Lina Badimon (Spain)

President of the Hellenic Cardiological Society

Stefanos Fousas (Greece)

Vice President of the Institute for the Study and Education
on Thrombosis and Antithrombotic Therapy

George Andrikopoulos (Greece)

Official opening

Governor, Region of Central Macedonia

Apostolos Tzitzikostas (Greece)

18.30-21:00 Round Table: Thrombosis: Pathophysiology-Pharmacology

Chairmen: **Lina Badimon (Spain)**

Stefanos Fousas (Greece)

18.30-18.50 Current scientific challenges into plaque rupture and
thrombosis in ACS

Lina Badimon (Spain)

18.50-19.10 The potential role of neutrophil extracellular traps (NETs)
in thrombogenesis

Dimitrios Stakos (Greece)

19.10-19.30 Thrombophilia in Pathogenesis of Hip Osteonecrosis

Anastasios Korompilias (Greece)

Friday, March 20th, 2015

- 19.30-19.50 Pleiotropic effects of antiplatelets. Underlying mechanisms and clinical implications
Alexandros Tselepis (Greece)
- 19.50-20.10 Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance
Marco Cattaneo (Italy)
- 20.10-20.30 Beta-Amyloid, Thrombosis and Cardiovascular Mortality
Konstantinos Stellos (Germany)
- 20.30-20.50 Thrombin generation. Pathophysiology and clinical significance
Grigoris Gerotziapas (France)
- 20.50-21.00 *Round Table discussion*

21.15

Dinner

Please present your coupon for admittance to the dinner

Saturday, March 21st, 2015

**08.30-10:00 Clinical Workshop: Antiplatelets and NOACS.
Improving clinical understanding and exploring
practical guidance**

Chairmen: **George Bobotis (Greece)**
Ioannis Tsounos (Greece)

ACS and active bleeding
Patient with AF under NOACs and presenting with STEMI
and no access to Pr PCI
History of PCI, AF and acute stroke
Chronic AF under warfarin and STEMI
STEMI -Pr PCI and episodes of AF
Known chronic CHD, congestive heart failure,
chronic Kidney disease and AF

Cases presenters:

**John Goudevenos, Panagiotis Korantzopoulos,
Dimitrios Nikas, Konstantinos Pappas**

Discussants:

**Dimitrios Alexopoulos, Ioannis Beis, Christos Graidis,
Dimokritos Dimitriadis, Thomas Papadopoulos,
Antonios Ziakas**

10.00-10.30 Coffee Break

10.30-11.00 Distinguished Lecture

Chairman: **Alexandros Tselepis (Greece)**

Cell-based regenerative therapies for cardiovascular
disease

Lina Badimon (Spain)

Saturday, March 21st, 2015**11.00-13.30 Round Table: Controversies in antiplatelet therapy**Chairmen: **Marco Cattaneo (Italy)****Dimitrios Alexopoulos (Greece)**

- 11.00-11.15 Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on Clinical Outcomes in NSTEMI-ACS
Marco Cattaneo (Italy)
- 11.15-11.30 Prehospital administration of ticagrelor or prasugrel in ACS STEMI. Lessons from ACCOAST the ATLANTIC study
John Kanakakis (Greece)
- 11.30-11.45 Stent thrombosis. Which is the attributed risk of antiplatelet drugs
Achilleas Zacharoulis (Greece)
- 11.45-12.00 Anti thrombotic therapy one year after ACS: Single, dual or triple therapy?
Periklis Davlouros (Greece)
- 12.00-12.15 Cangrelor: For all, for some or for none?
Dimitrios Alexopoulos (Greece)
- 12.15-12.30 Efficacy and safety of parenteral anticoagulants in ACS and PCI
George Hahalis (Greece)
- 12.30- 12.45 Standard of therapy for patients with ACS and AF: Triple therapy or time to drop aspirin?
Vassilios Voudris (Greece)
- 12.45-13.00 Optimal antithrombotic treatment in acute ischemic stroke / transient ischemic attack
Konstantinos Vemmos (Greece)
- 13.00-13.15 The use of antiplatelets in acute coronary syndromes: Guidelines versus cost in the times of the Greek crisis
Panagiotis Stafylas (Belgium)
- 13.15-13.30 *Round Table Discussion*

Saturday, March 21st, 2015

- 13.30-14.30 Round Table: New oral anticoagulants: Unresolved issues**
Chairmen: **Vasilis Vasilikos (Greece)**
Fragiskos Parthenakis (Greece)
- 13.30-13.45 Unresolved issues in atrial fibrillation. Do the problems of our patients always fit in the guidelines
George Andrikopoulos (Greece)
- 13.45-14.00 New oral anticoagulants in high risk patients
Dimitris Richter (Greece)
- 14.00-14.15 Potential antidotes for reversal of new oral anticoagulants. Current status and ongoing research
Alexandros Tselepis (Greece)
- 14.15-14.30 When and how to restart antithrombotic therapy after a major bleeding event?
Athanasios Pipilis (Greece)
-

14.30 -16.00 Break

- 16.00-18.30 Round Table: Venous thromboembolism**
Chairmen: **Alex Spyropoulos (USA)**
Athanasios Giannoukas (Greece)
- 16.00-16.30 Laboratory monitoring of the new oral anticoagulants. Will it be clinically useful?
Elmina Lefkou (Greece)
- 16.30-16.50 Factors that predict thrombosis in relatives of patients with venous thromboembolism
James Douketis (Canada)
- 16.50-17.05 Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE:
A critical approach
Miltiadis Matsagkas (Greece)

Saturday, March 21st, 2015

- 17.05-17.20 The role of parenteral anticoagulation in VTE in the era of NOACs
Athanasios Giannoukas (Greece)
- 17.20-17.40 Predicting the risk of venous thromboembolism in hospitalized medical patients
Alex Spyropoulos (USA)
- 17.40-18.00 NOACs for the prevention and treatment of venous thromboembolism in cancer patients
Grigoris Gerotziapas (France)
- 18.00-18.20 What is new in the recently published ESC guidelines for pulmonary embolism?
Georgios Chalikias (Greece)
- 18.20-18.30 *Round Table Discussion*

18.30-19.00 Coffee Break

19.00-21.00 Round Table: Antithrombotic therapy in invasive procedures

Chairmen: **James Douketis (Canada)**
Ioannis Tsolakis (Greece)

- 19.00-19.20 Periprocedural antiplatelet therapy
James Douketis (Canada)
- 19.20-19.35 Antithrombotic treatment during and after carotid interventions
Andreas Lazaris (Greece)
- 19.35-19.50 Antiplatelet/antithrombotic management in non coronary interventions
Emmanuel Vavouranakis (Greece)

Saturday, March 21st, 2015

19.50-20.05 Anticoagulant bridging therapy prior to non-cardiac surgery. Are there any differences when NOACs are being used?

Eleni Arnaoutoglou (Greece)

20.05-20.30 Prevention of DVT in Orthopaedics Surgery. Where do American European guidelines differ?

Savas-George Sourmelis (Greece)

20.30-21.00 *Round Table Discussion*

21.15

Dinner

Please present your coupon for admittance to the dinner

Sunday, March 22th, 2015**09.00-09.15 Lecture**

Anticoagulation and antiplatelet therapy in urological practice

Petros Tzimas (Greece)

09:15-09:45 Lecture

Chairmen: **Konstantinos Pappas (Greece),
Demokritos Tsoukatos (Greece)**

Antithrombotic drugs for ACS and PCI: Most of the year in Review

John Goudevenos (Greece)

09.45-12:30 Round Table: Short Oral Presentations of Ongoing Research on Thrombosis

Chairmen: **Konstantinos Pappas (Greece),
Demokritos Tsoukatos (Greece)**

OP01 TETHERED-LIGAND PEPTIDE ANALOGS OF PROTEASE-ACTIVATED RECEPTOR-4 (PAR-4) IN HUMAN PLATELETS: A STRUCTURE-FUNCTION ANALYSIS

I.C. Moschonas¹, T. Kellici², A.G. Tzakos², A.D. Tselepis¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Sector of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

OP02 PEPTIDE ANALOGUES, DERIVED FROM THE EXTRACELLULAR DOMAIN OF $\alpha_{IIb}\beta_3$, AS ALLOSTERIC INHIBITORS OF $\alpha_{IIb}\beta_3$ ACTIVATION

A. Gkourogianni¹, S. Papadaki¹, V. Trypou², E. Malisiova², V. Moussis², V. Tsikaris², D. Tsoukatos¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

OP03 THE ACIDIC PEPTIDE PAL-K-LEEDDEEGE FROM THE INTRACELLULAR DOMAIN OF α_{IIb} SUBUNIT, INHIBITS INTEGRIN $\alpha_{IIb}\beta_3$ "INSIDE-OUT" ACTIVATION INDUCED BY PAL-K-KVGFVKR

S. Papadaki¹, A. Gkourogianni¹, V. Koloka², V. Tsikaris², E. Panou-Pomonis², D. Tsoukatos¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

OP04 ANTITHROMBOTIC EFFECT OF TWO FORMULATIONS OF TRIFLUSAL, IN VITRO AND IN VIVO. A COMPARATIVE PHARMACODYNAMIC STUDY

S. Papadaki¹, I. Moschonas¹, P. Tatsidou¹, M. Peroulis², C. Tellis¹, A. Tselepis¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Vascular Unit, Department of Surgery, University Hospital of Ioannina, Ioannina, Greece*

OP05 INHIBITION OF PLATELET INTEGRIN-RECEPTOR $\alpha_{IIb}\beta_3$ IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER 5 DAYS OF DUAL ANTIPLATELET TREATMENT

A. Gkourogianni¹, M. Tsoumani¹, I. Ntalas², K. Kalantzi², J. Goudevenos², D. Tsoukatos¹, A. Tselepis¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece*

OP06 ONGOING RESEARCH ON THE DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF N-(SUBSTITUTED) N'-[2-(1H-PYRROL-2-YL-CARBONYL)-PHENYL]UREAS AS NEW INHIBITORS OF RECEPTOR P2Y

A.G. Sarantou¹, M. Fermeletzi¹, V.G. Chantzichristos², S. Papadaki², E. Mikros³, G. Lambrinidis³, A.D. Tselepis², G. Varvounis¹

¹Laboratory of Organic Chemistry, Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

²Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

³Department of Pharmaceutical Chemistry, School of Pharmacy, National and Kapodistrian University of Athens, Zografou, Athens, Greece

OP07 THROMBOSIS AND ANTITHROMBOTIC THERAPY. WHAT DO NURSES KNOW?

M. Ntalouka¹, P. Tzimas², A. Petrou¹, N. Siontis², G.M. Kostanasiou², A. Lena¹, E. Arnaoutoglou¹

¹Department of Anaesthesia and Postoperative Intensive Care, University Hospital of Ioannina, Ioannina, Greece,

²Cardiac Intensive Care Unit, University Hospital of Ioannina, Ioannina, Greece

OP08 RECURRENCE OF SUPERFICIAL VEIN THROMBOSIS IN PATIENTS WITH VARICOSE VEINS

Ch. Karathanos¹, K. Spanos¹, V. Saleptsis¹, A. Tsezou², D. Kyriakou³, A.D. Giannoukas¹

¹Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece

²Department of Laboratories of Molecular Biology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece

³Department of Genetics and Haematology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece

OP09 GENERIC CLOPIDOGREL BESYLATE IN THE SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS: A 6-MONTH FOLLOW-UP OF A RANDOMISED CLINICAL TRIAL

K.I. Kalantzi¹, V. Ntalas¹, M.E. Tsoumani², I. Vakalis², V. Vasilakopoulos², C. Vardakis², K. Vemmos³, M. Voukelatou², G. Giannakoulas⁴, I. Giatrakos², V. Giogiakas², G. Goumas⁵, N. Dimoulis², A. Draganigos⁶, I. Efthimiadis², M. Thoma², E. Kazakos², N. Kipouridis², S. Konstantinou², H. Milionis⁷, A. Mpourdakos⁸, D. Nikolopoulos², L. Peltekis², N. Prokopakis², I. Sinteles², C. Stroumbis², K. Terzoudi², K. Tsilias², I. Xaraktis², C. Charmpas², G. Hatziathanasiou², Z. Christogiannis², D.B. Panagiotakos⁹, J.A. Goudevenos¹, A.D. Tselepis²

¹*Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece*

²*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

³*Department of Clinical Therapeutics, Medical School of Athens, Alexandra Hospital, Athens, Greece*

⁴*First Cardiology Department, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece*

⁵*Department of Cardiology, Euroclinic, Athens, Greece*

⁶*Department of Cardiology, General Hospital of Corfu, Corfu Island, Greece,*

⁷*Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece,*

⁸*General Hospital of Trikala, Trikala, Greece,*

⁹*School of Health Science & Education, Harokopio University, Athens, Greece*

OP10 CRUSHED VS INTEGRAL TABLETS OF TICAGRELOR LOADING IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS: A PHARMACODYNAMIC AND PHARMACOKINETIC STUDY

D. Alexopoulos¹, N. Barampoutis¹, V.Gkizas¹, K. Kontoprias¹, Ch. Vogiatzi¹, G. Tsigkas¹, N. Koutsogiannis¹, P. Davlouros¹, G. Hahalis¹, S. Nylander², G. Parodi³, I. Xanthopoulou¹

¹*Department of Cardiology, Patras University Hospital, Rion, Patras, Greece*

²*AstraZeneca R&D, Mölndal, Sweden*

³*Cardiovascular and Thoracic Department, Careggi Hospital, Florence, Italy*

OP11 DIFFERENTIAL EFFECT OF TICAGRELOR VS THIENOPYRIDINE LOADING ON FRACTIONAL FLOW RESERVE

D. Alexopoulos¹, A. Perperis¹, P. Davlouros¹, G. Tsigkas¹, N. Koutsogiannis¹, A. Chasapi¹, Ch. Schortsanitis¹, I. Pentara¹, Ch. Vogiatzi¹, I. Xanthopoulou¹

¹*Department of Cardiology, Patras University Hospital, Rion, Patras, Greece*

OP12 CIRCULATING LEVELS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A₂ IN PATIENTS WITH ACUTE CORONARY SYNDROME RECEIVING CLOPIDOGREL

C.C.Tellis¹, M.E. Tsoumani¹, I.V. Ntalas², M.V. Chatziathanasiadou³, V.G. Kontogianni³, A.N. Katsikoudi³, A.G. Tzakos³, I.A. Goudevenos², A.D. Tselepis¹

¹*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

²*Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece*

³*Sector of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*

- OP13 DIABETES MELLITUS AND PLATELET REACTIVITY IN PATIENTS UNDER PRASUGREL OR TICAGRELOR TREATMENT**
D. Alexopoulos¹, Ch.Vogiatzi¹, K. Stavrou¹, N. Vlassopoulou¹,
A. Perperis¹, I. Pentara¹, I. Xanthopoulou¹
¹*Department of Cardiology, Patras University Hospital, Patras, Greece*
- OP14 PHARMACOMETABOLOMICS REVEAL THE RESISTANCE TO CLOPIDOGREL**
I.C. Moschonas², A.I. Milioni¹, D. Benaki¹, M.E. Tsoumani²,
N. Lemonakis¹, E. Gikas¹, A.D. Tselepis², E. Mikros¹
¹*Department of Pharmaceutical Chemistry, School of Pharmacy, University of Athens, Athens, Greece*
²*Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- OP15 FACTORS AFFECTING PLATELET REACTIVITY SHORTLY AFTER P2Y₁₂ RECEPTOR ANTAGONIST LOADING IN STEMI PATIENTS UNDERGOING PRIMARY PCI: THE IMPACT OF PAIN-TO-LOADING TIME**
I. Xanthopoulou¹, K. Kontoprias¹, P. Davlouros¹, G. Tsigkas¹,
N. Koutsogiannis¹, S. Patsilidakos², S. Deftereos³, G. Hahalas¹,
D. Alexopoulos¹
¹*Department of Cardiology, Patras University Hospital, Patras, Greece*
²*Konstantopouleio General Hospital, Athens, Greece*
³*"G. Genimatas" General Hospital, Athens, Greece*
- OP16 SUBGROUP ANALYSES OF THE EFFECT OF NOVEL ORAL ANTICOAGULANTS (NOACS) IN ATRIAL FIBRILLATION (AF)**
J. Goudevenos¹, K. Kalantzi², D. Nikas¹, P. Korantzopoulos¹,
A. Tselepis²
¹*Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece*
²*University of Ioannina, Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, Ioannina, Greece*

- Alexopoulos Dimitrios** Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece
- Andrikopoulos George** Cardiologist, Director, Department of Cardiology, "Henry Dunant" Hospital of Athens, Athens, Greece
- Arnautoglou Eleni** Associate Professor of Anaesthesiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Badimon Lina** Prof., Director of Cardiovascular Research Center (CSIC-ICCC) Institut Català de Ciències Cardiovasculars (ICCC) Hospital de la Santa Creu i Sant Pau, Spain
- Beis Ioannis** Consultant Cardiologist, Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece
- Bompotis George** Cardiologist, Director, Department of Cardiology, "Papageorgiou" General Hospital of Thessaloniki, Thessaloniki, Greece
- Cattaneo Marco** Professor of Internal Medicine, Department of Medicine, Surgery and Dentist Science. University of Milan, Director, 3rd Unit of Medicine, "San Paolo" Hospital, Milan, Italy
- Chalikias George** Lecturer in Cardiology University Department of Cardiology Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece
- Davlouros Periklis** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece

- Dimitriadis Dimokritos** Interventional Cardiologist, Kianos Stavros EUROMEDICA, Thessaloniki, Greece
- Douketis James** Professor of Internal Medicine, Division of Hematology and Thromboembolism, Department of Medicine, University of Toronto, Toronto, Canada
- Fousas Stefanos** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Athens, Director, Department of Cardiology, "Tzaneio" General Hospital of Piraeus, President, Hellenic Cardiological Society, Athens, Greece
- Gerotziapas Grigoris** Associate Professor of Hematology - Hemostasis, Faculty of Medicine, University Pierre et Marie Curie, Paris, France
- Giannoukas Athanasios** Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
- Goudevenos John** Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Graidis Christos** Interventional Cardiologist, Kianos Stavros EUROMEDICA, Thessaloniki, Greece
- Hahalis George** Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece
- Kanakakis John** Director of Catheterization Laboratory, Department of Clinical Therapeutics, "Alexandra" General Hospital of Athens, Greece
- Korantzopoulos Panagiotis** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece

- Korompilias Anastasios** Professor Orthopaedics, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Lazaris Andreas** Assistant Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece
- Lefkou Eleftheria- Elmina** Consultant Haematologist, Specialised in Haemostasis & Thrombosis Haemostasis & Thrombosis, Obstetric Haematology, Antiphospholipid Syndrome
- Matsagkas Miltiadis** Professor of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Nikas Dimitrios** Cardiologist, 1st Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece
- Papadopoulos Thomas** Interventional Cardiologist, Thessaloniki, Greece
- Pappas Konstantinos** Cardiologist, Department of Cardiology, University Hospital of Ioannina, Ioannina, Greece
- Parthenakis Fragiskos** Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Crete, Heraklion, Greece
- Pipilis Athanasios** Cardiologist, Director, 1st Department of Cardiology, "Hygeia" Diagnostic and Therapeutic Centre of Athens, Athens, Greece
- Richter Dimitrios** Director, Department of Cardiology, Euroclinic of Athens, Athens, Greece

- Sourmelis Savvas- George** Orthopaedic Surgeon, 2nd Department of Orthopaedics, "Hygeia" Diagnostic and Therapeutic Centre of Athens, Athens, Greece
- Spyropoulos Alex** Professor of Medicine, Hofstra-North Shore LIJ School of Medicine, Hofstra University, Director, Anticoagulation and Clinical Thrombosis Services, North Shore-LIJ Health System, Lenox Hill Hospital, New York, USA
- Stafylas Panagiotis** Cardiologist, Medical Coordinator of European Research Projects, HIM SA, Brussels, Belgium
- Stakos Dimitrios** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece
- Stellos Konstantinos** Professor of Medicine, Department of Cardiology, Center of Internal Medicine, Goethe University Frankfurt, Group-Leader, Vascular Inflammation Laboratory, European Cardiovascular Science Center, Frankfurt, Germany
- Tselepis Alexandros** Professor of Biochemistry-Clinical Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece
- Tsolakis Ioannis** Professor of Vascular Surgery Faculty of Medicine, School of Health Sciences, University of Patras, Patras, Greece
- Tsoukatos Dimokritos** Professor of Biological Chemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

- Tsounos Ioannis** Director, Department of Cardiology, "Agios Pavlos" General Hospital of Thessaloniki, Thessaloniki, Greece
- Tzimas Petros** Assistant Professor of Anaesthesiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
- Vasilikos Vassilios** Professor of Cardiology Faculty of Medicine, School of Health Sciences, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Vavouranakis Emmanuel** Assistant Professor of Cardiology, Faculty of Medicine, School of Health Sciences, University of Athens, Athens, Greece
- Vemmos Konstantinos** Stroke Internist, Hellenic Stroke Organization, Athens, Greece
- Voudris Vassilios** Cardiologist, Director, 2nd Division of Interventional Cardiology, Chairman, Department of Cardiology, "Onassis" Cardiac Surgery Center of Athens, Athens, Greece
- Zacharoulis Achilleas** Consultant Cardiologist, 2nd Department of Cardiology, "Attikon" University General Hospital of Athens, Athens, Greece
- Ziakas Antonios** Associate Professor of Cardiology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Greece

The Organizers wish to thank the following pharmaceutical and / or equipment / device companies for their support in the accomplishment of the course:

Major Sponsors



Sponsors



Clovelen®

Clopidogrel

ΕΠΩΝΥΜΟ
ΕΛΛΗΝΙΚΟ
ΦΑΡΜΑΚΟ



ΑΡΧΕΤΥΠΟ
ΕΛΠΕΝ

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Clovelen® 75 mg επικαλυμμένα με λεπτό υμένιο δισκία.
ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΩΤΙΚΗ ΣΥΝΘΕΣΗ: Κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 75mg clopidogrel (κλοπιδογρέλης), ως besilate. Έκδοχα: κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει 2.6mg μονούδρικης λακτόζης.

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.

Με την εγγύηση της



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ

Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής, Τηλ.: 210 6039326-9, Fax: 210 6039300

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ

Σεβαστείας 11, 115 28 Αθήνα, Τηλ.: 210 7488711, Fax: 210 7488731


Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη, Τηλ.: 2310 459920-1, Fax: 2310 459269

DuoPlavin®

Clpidogrel 75mg/ASA 100mg

ΚΛΟΠΙΔΟΓΡΕΛΗ 75mg

ΑΣΟ 100mg



Plavix®

(clopidogrel hydrogen sulphate)

75 mg and 300 mg tablets

Πριν τη συνταγογράφηση των προϊόντων συμβουλευτείτε τις Π.Χ.Π. που βρίσκονται στον ιστότοπο της εταιρείας www.sanofi.gr.
Για περισσότερες πληροφορίες απευθυνθείτε στο Τμήμα Ιατρικής Πληροφόρησης της Sanofi στο τηλέφωνο 210 9001600 ή στην ηλεκτρονική διεύθυνση medicalinformation.greece@sanofi.com.

GR.CLO.15.01.04

SANOFI 


Sanofi-aventis A.E.B.E. Λεωφ. Συγγρού 348, Κτίριο Α', 176 74 Καλλιθέα.
Τηλ.: 210 90 01 600, Fax: 210 92 49 342, www.sanofi.gr



Xarelto[®]

rivaroxaban

15mg & 20mg



Bayer

Κάτοχος της άδειας κυκλοφορίας:
Bayer Pharma AG, 13342 Berlin, Γερμανία
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Ελλάδα: Bayer Ελλάς ABEE, Σωρού
18-20, 151 25 Μαρούσι,
Τοπικός αντιπρόσωπος του κατόχου άδειας
κυκλοφορίας στην Κύπρο: Novagem Ltd,
Τηλ.00357 22483858

Τμήμα Επιστημονικής Ενημέρωσης
Τηλ: +30 210 6187742, Fax: +30 210 6187522
Email: medinfo.gr.cy@bayer.com

Εταιρεία συμπτώθησης



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ
Λεωφ. Μιχαράδωνος 95, 190 09 Πικέρμι Αττικής,
Τηλ: 210 6039326 - 9, Fax: 210 6039300
ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ
Σεβαστείας 11, 115 28 Αθήνα,
Τηλ: 210 7488711, Fax: 210 7488731
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,
Τηλ: 2310 459920 - 1, Fax: 2310 459269

LOGO/009/2014/0371

Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη των Χαρακτηριστικών του Προϊόντος που διατίθεται στο εκθετήριο

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»